Cardiovascular disease burden in patients with urological cancers: The new discipline of uro‐cardio‐oncology

Cancer remains a major cause of mortality worldwide, and urological cancers are the most common cancers among men. Several therapeutic agents have been used to treat urological cancer, leading to improved survival for patients. However, this has been accompanied by an increase in the frequency of su...

Full description

Saved in:
Bibliographic Details
Published in:Cancer innovation (Print) 2024-04, Vol.3 (2), p.e108-n/a
Main Authors: Zheng, Yi, Liu, Ying, Chen, Ziliang, Zhang, Yunpeng, Qi, Zuo, Wu, Ning, Zhao, Zhiqiang, Tse, Gary, Wang, Yong, Hu, Hailong, Niu, Yuanjie, Liu, Tong
Format: Article
Language:English
Subjects:
Androgens
anticancer therapy
Cancer therapies
Cardiac arrhythmia
Cardiovascular disease
cardiovascular toxicity
Cell death
Cholesterol
Clinical trials
Diabetes
Fatalities
Heart attacks
Heart failure
Hypertension
Ischemia
Kinases
Lipoproteins
mechanism
Medical prognosis
Metabolic disorders
Metastasis
Mortality
multidisciplinary management
Oncology
Public health
Risk factors
Toxicity
Urological cancer
Vascular endothelial growth factor
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer remains a major cause of mortality worldwide, and urological cancers are the most common cancers among men. Several therapeutic agents have been used to treat urological cancer, leading to improved survival for patients. However, this has been accompanied by an increase in the frequency of survivors with cardiovascular complications caused by anticancer medications. Here, we propose the novel discipline of uro‐cardio‐oncology, an evolving subspecialty focused on the complex interactions between cardiovascular disease and urological cancer. In this comprehensive review, we discuss the various cardiovascular toxicities induced by different classes of antineoplastic agents used to treat urological cancers, including androgen deprivation therapy, vascular endothelial growth factor receptor tyrosine kinase inhibitors, immune checkpoint inhibitors, and chemotherapeutics. In addition, we discuss possible mechanisms underlying the cardiovascular toxicity associated with anticancer therapy and outline strategies for the surveillance, diagnosis, and effective management of cardiovascular complications. Finally, we provide an analysis of future perspectives in this emerging specialty, identifying areas in need of further research. Treatment‐induced cardiovascular toxicity is linked to ADT, VEGFR‐TKIs, ICIs, and chemotherapy. We propose the new discipline of uro‐cardio‐oncology to address the relationship between cardiovascular disease and urological cancers. ADT, androgen deprivation therapy; ICI, immune checkpoint inhibitor; VEGFR‐TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor.
ISSN:2770-9191
2770-9183
2770-9183
DOI:10.1002/cai2.108